Abstract Objective In Europe, eslicarbazepine acetate (ESL) is approved as adjunctive
therapy for the treatment of focal seizures (FS) in children aged> 6 years. In the US, ESL is …

Purpose This was a phase-III, randomized, double-blind, placebo-controlled study aimed to
evaluate efficacy and tolerability of eslicarbazepine acetate (ESL) as adjunctive therapy in …

Objective The objective of this study was to evaluate long-term safety and tolerability
outcomes in two open-label extension (OLE) studies of adjunctive eslicarbazepine acetate …

Objective: To evaluate the safety and tolerability of adjunctive eslicarbazepine acetate (ESL)
in pediatric patients (aged 4-17 years) with refractory focal seizures. Methods: Pooled safety …

Purpose This was a phase-II, randomized, double-blind (DB), placebo-controlled study
aimed to evaluate neurocognitive effects of eslicarbazepine acetate (ESL) as adjunctive …

Eslicarbazepine acetate (ESL) is a once daily new third generation antiepileptic drug that
shares the basic chemical structure of carbamazepine and oxcarbazepine–a dibenzazepine …

Methods: Children (2–18years) with POS (≥ 4 in the month before enrolment), receiving 1-2
antiepileptic-drugs (except oxcarbazepine), were randomized (1: 1) to ESL or placebo. ESL …

Eslicarbazepine acetate (Zebinix®), a voltage-gated sodium channel blocker, is a once-
daily, orally administered anti-seizure medication available in the EU for use as …

Objective: To determine the safety and tolerability of adjunctive ESL for POS in pediatric
patients. Background: The prevalence of epilepsy is high in childhood. ESL is a once-daily …

Eslicarbazepine acetate (ESL), a new voltage-gated sodium channel blocker that is
chemically related to carbamazepine and partially metabolized to oxcarbazepine, has …